202 related articles for article (PubMed ID: 20606683)
1. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.
Henry NL; Pchejetski D; A'Hern R; Nguyen AT; Charles P; Waxman J; Li L; Storniolo AM; Hayes DF; Flockhart DA; Stearns V; Stebbing J
Br J Cancer; 2010 Jul; 103(3):291-6. PubMed ID: 20606683
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Lintermans A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
Ann Oncol; 2011 Aug; 22(8):1763-9. PubMed ID: 21273342
[TBL] [Abstract][Full Text] [Related]
3. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
Roberts K; Rickett K; Greer R; Woodward N
Crit Rev Oncol Hematol; 2017 Mar; 111():66-80. PubMed ID: 28259297
[TBL] [Abstract][Full Text] [Related]
4. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
5. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
[TBL] [Abstract][Full Text] [Related]
6. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
Hyder T; Marino CC; Ahmad S; Nasrazadani A; Brufsky AM
Front Endocrinol (Lausanne); 2021; 12():713700. PubMed ID: 34385978
[TBL] [Abstract][Full Text] [Related]
7. The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
Shanmugam VK; McCloskey J; Elston B; Allison SJ; Eng-Wong J
Breast Cancer Res Treat; 2012 Jan; 131(2):699-708. PubMed ID: 22076476
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
[TBL] [Abstract][Full Text] [Related]
9. Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.
Liang Y; Gersch CL; Lehman J; Henry NL; Smith KL; Rae JM; Stearns V; Hertz DL
Pharmacogenet Genomics; 2024 Jun; 34(4):126-129. PubMed ID: 38359166
[TBL] [Abstract][Full Text] [Related]
10. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
[TBL] [Abstract][Full Text] [Related]
11. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.
Lintermans A; Laenen A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
Ann Oncol; 2013 Feb; 24(2):350-355. PubMed ID: 23038762
[TBL] [Abstract][Full Text] [Related]
12. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
Santa-Maria CA; Bardia A; Blackford AL; Snyder C; Connolly RM; Fetting JH; Hayes DF; Jeter SC; Miller RS; Nguyen A; Quinlan K; Rosner GL; Slater S; Storniolo AM; Wolff AC; Zorzi J; Henry NL; Stearns V
Breast Cancer Res Treat; 2018 Aug; 171(1):121-129. PubMed ID: 29752687
[TBL] [Abstract][Full Text] [Related]
13. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors.
Bao T; Cai L; Giles JT; Gould J; Tarpinian K; Betts K; Medeiros M; Jeter S; Tait N; Chumsri S; Armstrong DK; Tan M; Folkerd E; Dowsett M; Singh H; Tkaczuk K; Stearns V
Breast Cancer Res Treat; 2013 Feb; 138(1):167-74. PubMed ID: 23393007
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.
Hertz DL; Douglas JA; Miller RM; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM
Support Care Cancer; 2022 Oct; 30(10):8059-8067. PubMed ID: 35776183
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.
Henry NL; Jacobson JA; Banerjee M; Hayden J; Smerage JB; Van Poznak C; Storniolo AM; Stearns V; Hayes DF
Cancer; 2010 Sep; 116(18):4360-7. PubMed ID: 20549827
[TBL] [Abstract][Full Text] [Related]
16. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.
Martínez N; Herrera M; Frías L; Provencio M; Pérez-Carrión R; Díaz V; Morse M; Crespo MC
Clin Transl Oncol; 2019 Apr; 21(4):489-498. PubMed ID: 30293230
[TBL] [Abstract][Full Text] [Related]
17. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Gallicchio L; Macdonald R; Wood B; Rushovich E; Helzlsouer KJ
Breast Cancer Res Treat; 2011 Nov; 130(2):569-77. PubMed ID: 21647676
[TBL] [Abstract][Full Text] [Related]
18. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
[TBL] [Abstract][Full Text] [Related]
19. Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.
Wang J; Lu K; Song Y; Xie L; Zhao S; Wang Y; Sun W; Liu L; Zhao H; Tang D; Ma W; Pan B; Xuan Q; Liu H; Zhang Q
PLoS One; 2013; 8(7):e68798. PubMed ID: 23894347
[TBL] [Abstract][Full Text] [Related]
20. Intergroup Exemestane Study mature analysis: overall survival data.
Jassem J;
Anticancer Drugs; 2008 Feb; 19 Suppl 1():S3-7. PubMed ID: 18340242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
